Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: UMLS:C0020505 (
hyperphagia
)
6,116
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
There is evidence for reciprocal interactions between the brain monoamine neurotransmitters serotonin and noradrenaline which may play a critical role in homeostasis. The aim of the present study was to establish the effect of drug-induced damage to the serotoninergic system on noradrenergic activity in the hypothalamus. Bilateral intracerebroventricular injections of p-chlorophenylalanine (PCPA; 3 mg/kg in 2 x 6 microliters) were made to induce destruction in the serotoninergic system. Relative to saline-injected controls, PCPA-injected rats began
overeating
by 3 days postinjection. On day 10, when the experimental rats were consuming approximately 120% that of controls, animals were 4-h food deprived, sacrificed and the medial basal hypothalamus was removed for later analysis (by gas chromatography/mass spectrometry) of noradrenaline (NA), serotonin (
5-HT
) and dopamine (DA) and their principal metabolites dihydroxyphenylethyleneglycol (DHPG), 5-hydroxyindoleacetic acid (5-HIAA) and 3,4-dihydroxyphenylacetic acid (DOPAC), respectively. The ratio of metabolite to monoamine provided an index of functional activity. Trunk blood was collected for analysis of serum insulin and glucose. PCPA-injected animals had higher levels of DHPG (P less than 0.05), an increase in the DHPG/NA ratio (P less than 0.02), lower serum insulin (P less than 0.05) and increased serum glucose (P less than 0.05). There were significant correlations between noradrenergic activity (DHPG/NA ratio) and: (1) food intake (day 9 and 10 average; r = 0.62, P less than 0.05); and (2) serum glucose (r = 0.59, P less than 0.05).(ABSTRACT TRUNCATED AT 250 WORDS)
...
PMID:Medial basal hypothalamic monoamine activity associated with intracerebroventricular p-chlorophenylalanine-induced hyperphagia. 214 5
Feeding or food withdrawal can affect the supply of tryptophan to the brain and hence (in some circumstances)
5-HT
synthesis therein. Also fenfluramine which releases
5-HT
to postsynaptic receptors suppresses appetite, and there are reports that tryptophan can have a similar effect. Furthermore, feeding is reported to release hypothalamic
5-HT
. Therefore
5-HT
could have a role in the normal termination of feeding and perhaps also in disorders of appetite. The recognition of various 5-HT receptor subtypes has stimulated research in this area. We have now investigated the involvement of the subtypes in the pharmacological control of feeding. Thus, 5-HT1A agonists (8-OHDPAT, buspirone, gepirone, etc.) stimulate intake in freely feeding rats, probably by activating autoreceptors on the cell bodies of
5-HT
neurons so that
5-HT
release at terminals is decreased. The
hyperphagia
is not explicable by increased activity or gnawing and is strikingly manifest against carbohydrate in carbohydrate vs. protein choice experiments. Feeding in previously food-deprived rats is decreased by the
5-HT
agonists RU 24969, 1-(3-chlorophenyl) piperazine (mCPP) and 1-(3-trifluoromethyl) phenyl) piperazine (TFMPP). Effects of antagonists on these properties suggest that RU 24969-induced hypophagia depends on 5-HT1B receptors only, while mCPP and TFMPP induce hypophagia at 5-HT1C sites, though this effect also requires 5-HT1B receptors for its expression. Responsible sites occur in the paraventricular nucleus of the hypothalamus as infusing either RU 24969 or TFMPP therein causes hypophagia. On systemic injection, the hypophagic drugs are particularly active in female rats, an effect of conceivable relevance to human anorexic illness.
...
PMID:Serotonin and appetite. 225 31
Administration of 60 micrograms/kg s.c. of the 5-HT1A agonist 8-hydroxy-2-(di-n-propylamino)-tetralin (8-OH-DPAT), a dose previously shown to cause
hyperphagia
in satiated rats (but not to cause the
5-HT
behavioural syndrome) decreased 5-HIAA and 5-HIAA/
5-HT
ratio in several brain regions, the most marked effects being in pons + medulla oblongata, a region containing
5-HT
cell bodies and ascending
5-HT
axons. Micro-infusion of 8-OH-DPAT (250 and 500 ng) into the dorsal or medial raphe nuclei significantly increased food intake and feeding duration but did not produce the
5-HT
behavioural syndrome. Results suggest that 8-OH-DPAT induced
hyperphagia
is mediated via a agonist action on somatodendritic
5-HT
autoreceptors.
...
PMID:Neurochemical and behavioural evidence for mediation of the hyperphagic action of 8-OH-DPAT by 5-HT cell body autoreceptors. 243 Aug 15
The present study was undertaken to investigate the hyperphagic responses to the 5-HT1A receptor agonist, 8-hydroxy-2-(di-n-propylamino)tetralin (8-OH-DPAT), in young and adult rats fed either a powder diet or pellets. In the young rats, 8-OH-DPAT (500 micrograms/kg s.c.) increased the consumption of pellets--but not powder--during the 2 h following drug administration. On the other hand, 8-OH-DPAT did not promote
hyperphagia
in adult rats presented with either pellets or a powdered diet. The influence of the 5-HT1A agonist on midbrain serotonin (5-hydroxytryptamine,
5-HT
) turnover was examined. Administration of 8-OH-DPAT (500 micrograms/kg s.c.) induced similar decreases in
5-HT
turnover, as reflected by the ratio of 5-hydroxyindoleacetic acid (5-HIAA) to
5-HT
, in young and adult rats 1 h after administration. Nevertheless, some metabolic responses to 8-OH-DPAT were found to be influenced by age. Young and adult rats were injected with a low dose of 8-OH-DPAT (50 micrograms/kg s.c.) to specifically test the presynaptic regulation of
5-HT
turnover. Again, midbrain 5-HIAA to
5-HT
ratios were decreased to the same extent in both young and adult rats. The results suggest that (i) gnawing may be an important parameter in the food consumption that is triggered by a high dose of 8-OH-DPAT, (ii) analysis of the presynaptic effects of 8-OH-DPAT on
5-HT
turnover cannot solely explain the influence of the agonist on feeding behavior.
...
PMID:Feeding responses to a high dose of 8-OH-DPAT in young and adult rats: influence of food texture. 245 45
This minireview deals with the possible roles of monoamines in feeding and feeding disorders. The introduction sketches the results of earlier studies with local drug injections and selective neurotoxins which provided pharmacological evidence that monoamines can influence food intake and body weight. A table summarizing this evidence is used to list monoamine changes that could underlie anorexia or
hyperphagia
. It is apparent that abnormalities in the monoamines, along with their cotransmitters, could cause many forms of feeding disorder. It is proposed as a working hypothesis that several varieties of
hyperphagia
leading to obesity have a common element. This common factor is a change in excitability of a lateral hypothalamic reinforcement system as manifested in self-stimulation at a stimulation-bound feeding site. Understanding this feeding reward-aversion system helps us understand
hyperphagia
and anorexia. The neurochemistry of reward and aversion involves the monoamines. This paper focuses on dopamine and serotonin. The data support the hypothesis that dopamine systems projecting to the nucleus accumbens and other forebrain areas from the mid-brain ventral tegmental area (VTA) are important for approach and positive reinforcement in ingestive behavior and self-stimulation.
Serotonin
is hypothesized to facilitate satiety and inhibition of feeding reward in the hypothalamus. The next section abstracts our recent experiments that measured pharmacological and physiological release of the monoamines in the hypothalamus and nucleus accumbens during ingestive behavior and self-stimulation. In vivo microdialysis in freely moving rats suggested the following: (1) Norepinephrine was released in the paraventricular nucleus during the active, feeding period of the circadian cycle. (2) The serotonin metabolite 5-HIAA also increased in the PVN at the same time if there was food to eat. (3) Amphetamine infused into the lateral hypothalamus (LH) by reverse dialysis increased synaptic dopamine, norepinephrine, and serotonin. (4) The anorectic drug d-fenfluramine increased synaptic serotonin in the LH and also increased the dopamine metabolite DOPAC, suggesting that serotonin and dopamine in the LH might contribute to fenfluramine-induced satiety. Local d-fenfluramine injection into the LH or local infusion by reverse dialysis again increased serotonin and decreased 5-HIAA and interfered with local dopamine metabolism as reflected in decreased DOPAC and HVA. (5) Tryptophan, a serotonin precursor, given systemically at an anorectic dose, increased extracellular serotonin in the LH, but this effect was only detectable in food-deprived rats. This was seemingly pH independent (between 5.8 and 8). The passage other cations through CFo is strictly suppressed (even at pH 8 and with 300 mM NaCl in the medium).(ABSTRACT TRUNCATED AT 400 WORDS)
...
PMID:Microdialysis studies of brain norepinephrine, serotonin, and dopamine release during ingestive behavior. Theoretical and clinical implications. 269 87
The putative serotonin (
5-HT
)1A agonist 1-[2-(4-aminophenyl)ethyl]-4-(3-trifluormethylphenyl) piperazine (LY165163, PAPP) induces
hyperphagia
and hypothermia in rats, but unlike other
5-HT
agonists, does not induce
5-HT
stereotypy even at high doses (10 mg/kg sc). LY165163 (1 mg/kg) increased striatal DOPA accumulation in animals treated with the aromatic amino acid decarboxylase inhibitor 3-hydroxy-benzylhydrazine (NSD 1015) (100 mg/kg ip). This increase was also found when the drug was given to animals pretreated with parachlorophenylalanine (pCPA) (150 mg/kg ip daily for 3 days). LY165163 (2 and 4 mg/kg sc) inhibited stereotyped behaviour induced by the dopamine (DA) agonist apomorphine (2 mg/kg sc). LY165163 (2, 4, 10 mg/kg sc) also inhibited stereotyped components of the
5-HT
syndrome induced by 5-methoxy-N,N-dimethyltryptamine (5-MeODMT; 5 mg/kg ip) which previous studies (e.g. Andrews et al. 1982) suggested to require DA (head weaving, reciprocal forepaw treading). Thus, while other 5-HT1A agonists such as 8-hydroxy-2-(di-n-propylamino) tetralin (8-OH-DPAT) cause stereotypy, this does not occur with LY165163, probably because the drug blocks DA receptors.
...
PMID:Blockade of dopamine receptors explains the lack of 5-HT stereotypy on treatment with the putative 5-HT1A agonist LY165163. 295 21
The 5-HT1A agonist, 8-hydroxy-2-(di-n-propylamino) tetralin (8-OH-DPAT) at a dose of 1 mg/kg s.c. increased food intake in free feeding rats. 8-OH-DPAT-induced feeding was blocked by metergoline which has comparable affinity for 5-HT1A, 5-HT1B, 5-HT1C and 5-HT2 receptors. This is consistent with the
hyperphagia
being mediated by an action at
5-HT
receptors. Evidence against the involvement of 5-HT2 or 5-HT3 receptors was provided by the lack of effect of methysergide, ketanserin, MDL 72222 and ICS 205930 on the feeding response. Blockade of the
hyperphagia
by (-)- but not (+)pendolol which stereoselectively interacts with 5-HT1 receptors indicated an involvement of this receptor type. The lack of effect of ketanserin suggests that the 5-HT1C site is not involved as it has high affinity for both 5-HT2 and 5-HT1C receptors. Blockade of the
hyperphagia
by spiperone suggests mediation by 5-HT1A rather than 5-HT1B receptors. Although spiperone also blocks dopamine and alpha 2-adrenoreceptors, involvement of these sites is unlikely as neither the DA antagonist haloperidol nor the alpha 2-adrenoceptor antagonist idazoxan blocked 8-OH-DPAT-induced feeding. These results indicate that 8-OH-DPAT-induced feeding is mediated by 5-HT1A receptors.
...
PMID:Evidence that the hyperphagic response to 8-OH-DPAT is mediated by 5-HT1A receptors. 297 Sep 74
The efficacy of anorectic drugs has been studied in rats made hyperphagic by injection of insulin or of 2-deoxy-d-glucose (2-DG). It was found that anorectics that act through a serotoninergic mechanism, i.e., d- and d-l-fenfluramine, p-chloroamphetamine, quipazine and fluoxetine antagonize both insulin- and 2-DG-induced
overeating
, while anorectics acting through the dopaminergic system, i.e., d-amphetamine, diethylpropion, lisuride, bromocriptine and mazindol, antagonize the
hyperphagia
induced by 2-DG but not that induced by insulin. Neither serotoninergic nor dopaminergic anorectics modified insulin-induced hypoglycaemia. The serotonin (
5-HT
) receptor blocker metergoline did not modify the hyperphagic response to insulin or 2-DG. The present results indicate that there are different neuronal or humoral circuits underlying the hyperphagic responses to insulin and 2-DG. In addition, these results, which show different effectiveness of anorectic drugs depending on what has provoked the
hyperphagia
, suggest that differences in the etiology of the
hyperphagia
of obese subjects must be taken into consideration when choosing therapy.
...
PMID:Dopaminergic and serotoninergic anorectics differentially antagonize insulin- and 2-DG-induced hyperphagia. 298 7
Experimental manipulations of
5-HT
by central or peripheral procedures produce clear effects on food intake. Interpretation of these effects can be improved by monitoring changes in the behavioural structure of feeding and by designing experiments which adjust the contextual and temporal dimensions of feeding. Experimental techniques include micro-analysis of behaviour, macro-analysis of meal patterns, dietary self-selection of macro-nutrients, analysis of appetite and satiety sequences, appetitive and consummatory aspects of instrumental performance and dietary-induced
hyperphagia
. Using these procedures in conjunction with various pharmacological treatments including the administration of tryptophan, 5-hydroxy-tryptophan,
5-HT
, re-uptake blockers, synaptic releasers, synthesis blockers, receptor blockers and others it has been demonstrated that
5-HT
manipulations give rise to a specific constellation of changes in feeding parameters. The most prominent changes following peripheral or central (paraventricular nucleus) injections are a reduction in meal size and a curtailment of eating rate. These changes can be distinguished from those induced by other pharmacological treatments and are consistent with a modulation of the process of satiation and the state of satiety. Changes in feeding induced by
5-HT
manipulations are not secondary to non-specific behavioural alterations.
...
PMID:Serotonin manipulations and the structure of feeding behaviour. 352 61
The intrathecal (IT) injection of serotonin in the rat was found to produce a variety of behavioral signs of the serotonin "syndrome" as well as intense gnawing.
Serotonin
-induced gnawing is qualitatively similar to that evoked by tail pinch. Paradoxically, tail pinch-induced gnawing has been previously shown to be inhibited by serotonergic activity while we found a positive dose-related correlation between the IT administration of serotonin and gnawing. Pretreatment with methysergide IT completely blocked gnawing produced by intrathecally injected serotonin but not that evoked by tail pinch. In contrast, naloxone, reported to inhibit tail pinch-induced
hyperphagia
, failed to affect serotonin-induced gnawing. The parenteral injection of haloperidol inhibited both tail pinch-induced and serotonin-induced gnawing. Failure of intrathecally injected haloperidol to inhibit serotonin-induced gnawing indicates that dopamine mediates this behavior at a supraspinal level. The ability of serotonin to elicit gnawing when injected at the spinal cord level, but to inhibit the same behavior when evoked by tail pinch, suggest that this neurotransmitter plays opposite roles depending on which part of the CNS is involved.
...
PMID:Serotonin-induced gnawing in rats: comparison with tail pinch-induced gnawing. 689 37
<< Previous
1
2
3
4
5
6
7
8
9
10
Next >>